Solstice Oncology emerged from stealth and anchored its next step in CTLA-4 immunotherapy with a new $225 million Series A, led by RA Capital Management and joined by other investors including Canaan Partners and Forbion. The funding is tied to porustobart, a next-generation CTLA-4 antibody aimed at improving responses in microsatellite-stable colon cancer. Opus Genetics also advanced in rare ophthalmology with early-stage gene therapy data for its OPGx-BEST1 program, which targets BEST1 mutations causing Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. The Phase I/II results set the company on a path toward pivotal work, as no therapies are currently approved for either condition. These two moves reflect a concentrated push into immunotherapy mechanisms and into asset-light, genetics-driven modalities where early signals can quickly reframe development trajectories and financing timelines.